Waxman’s Generic Reform: No 30-Month Stay, Early Declaratory Judgments
Rep. Henry Waxman (D-Calif.) is developing generic drug reform legislation that would eliminate the 30-month stay of approvals on ANDAs subject to patent litigation
Rep. Henry Waxman (D-Calif.) is developing generic drug reform legislation that would eliminate the 30-month stay of approvals on ANDAs subject to patent litigation